Inventor
Ryszard Kole
Inventor
Corvallis, OR, US
Overview
Patents· 27 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C12Nprimary
C12NMicroorganisms or enzymes34%
A61KPreparations for medical, dental or toiletry purposes29%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations26%
C07KPeptides9%
C07HSugars1%
Y02ATechnologies for adaptation to climate change1%
PatentTitleYear
11,071,749Oligonucleotide analogues targeting human LMNA202110,927,378Compound and method for treating myotonic dystrophy202110,822,608Oligonucleotide analogues targeting human LMNA202010,398,721Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA201910,106,796Compound and method for treating myotonic dystrophy201810,076,536Oligonucleotide analogues targeting human LMNA20189,833,468Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA20179,682,097'Oligonucleotide analogues targeting human LMNA'20179,453,225'Multiple exon skipping compositions for DMD'20169,447,416'Multiple exon skipping compositions for DMD'20169,447,417'Multiple exon skipping compositions for DMD'20169,434,948'Multiple exon skipping compositions for DMD'20169,326,992'Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA'20169,234,198'Multiple exon skipping compositions for DMD'20169,157,081'Chimeric oligomeric compounds for modulation of splicing'20159,066,967'Oligonucleotide analogues targeting human LMNA'20158,871,918'Multiple exon skipping compositions for DMD'20148,865,883'Multiple exon skipping compositions for DMD'20148,835,402'Compound and method for treating myotonic dystrophy'20148,741,863'Compound and method for treating myotonic dystrophy'20148,501,703'Chimeric oligomeric compounds for modulation of splicing'20137,884,194'Soluble HER2 and HER3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease'20117,785,834'Soluble TNF receptors and their use in treatment of disease'20105,976,879'Antisense oligonucleotides which combat aberrant splicing and methods of using the same'19995,916,808'Antisense oligonucleotides which combat aberrant splicing and methods of using the same'19995,665,593'Antisense oligonucleotides which combat aberrant splicing and methods of using the same'19975,627,274'Antisense oligonucleotides which combat aberrant splicing and methods of using the same'1997Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1997–2010Patents assigned to UNIV NORTH CAROLINA (5)· patent assignee history
1997–2015Based in Chapel Hill, NC, US· patent location history
1997Based in Orange County, NC, US· patent location history
2011–2021Based in Corvallis, OR, US· patent location history
2013–2014Patents assigned to KOLE RYSZARD (3)· patent assignee history
2014–2021Patents assigned to SAREPTA THERAPEUTICS INC (19)· patent assignee history
2014–2016Based in Bellevue, WA, US· patent location history
2016–2020Patents assigned to UNIV MARYLAND (4)· patent assignee history
2016–2020Patents assigned to US HEALTH (4)· patent assignee history
2020–2021Based in Cambridge, MA, US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| SAREPTA THERAPEUTICS INC | 19 | 2014–2021 |
| UNIV NORTH CAROLINA | 5 | 1997–2010 |
| UNIV MARYLAND | 4 | 2016–2020 |
| US HEALTH | 4 | 2016–2020 |
| KOLE RYSZARDself | 3 | 2013–2014 |
Locations
| Location | Patents | Span |
|---|---|---|
| Corvallis, OR, US | 11 | 2011–2021 |
| Bellevue, Washington, US | 7 | 2014–2016 |
| Chapel Hill, NC, US | 6 | 1997–2015 |
| Cambridge, Massachusetts, US | 2 | 2020–2021 |
| Orange County, NC, US | 1 | 1997 |